Maximize insights. Minimize tissue. One comprehensive panel
TSO 500 HT streamlines solid tumor profiling by combining DNA and RNA sequencing into a single, comprehensive assay. This approach enables biomarker identification, target validation, and patient stratification, helping to accelerate precision oncology development.
- 517 cancer-relevant genes
- DNA: SNVs, InDels and CNVs – 517 genes
- RNA: Fusions & splice variants – 55 genes
- IO gene signatures - MSI and TMB
- High performance DNA + RNA sequencing for optimized fusion detection
| Variant Class | Analytical Sensitivity | Specificity | Accuracy |
|---|---|---|---|
| SNVs | 95.2% | >99.9% | 99.9% |
| InDels | 92.4% | >99.9% | 99.9% |
| CNVs | 100% | 99.6% | 99.7% |
| Fusions | 94.4% | 99.9% | 99.7% |
| LOD | 5% VAF for small variants CNV reporting cutoff is 2.2X fold-change |
CTA style
Default